Stay updated on Expanded Access Risdiplam in SMA Clinical Trial
Sign up to get notified when there's something new on the Expanded Access Risdiplam in SMA Clinical Trial page.

Latest updates to the Expanded Access Risdiplam in SMA Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has removed detailed information about an Expanded Access Program for risdiplam in patients with spinal muscular atrophy, including eligibility criteria and exclusion criteria, while adding a new version number for the page.SummaryDifference23%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Expanded Access Risdiplam in SMA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Expanded Access Risdiplam in SMA Clinical Trial page.